Teva planned for second generic Copaxone to enter market in 2018

TEL AVIV (Reuters) - Israel-based Teva Pharmaceutical Industries said on Tuesday it had anticipated and planned for a second generic competitor to its multiple sclerosis treatment Copaxone to enter the market in 2018. Teva’s comments came after Novartis’s Sandoz division said it has won U.S. approval for a larger dosage of its Glatopa drug for MS patients, its copy of Copaxone. “We remain commi...